Search
calcifediol; 25-OH cholcalciferol; 25-OH vitamin D3 (Calderol)
Tradename: Calderol.
Indications:
1) metabolic bone disease
2) hypocalcemia in patients with renal failure
3) vitamin D deficiency
4) hypophosphatemia [2] (VITAMIN_D_DEFICIENCY HYPOPHOSPHATEMIA)
Dosage:
1) 300-350 ug/week administered daily or on alternate days (50 ug PO QD)
2) dose may be increased at 4 week intervals if adequate response is not observed
Pharmacokinetics:
1) readily absorbed from intestine
2) absorption may be reduces by liver or biliary disease or steatorrhea
3) 1/2life of several weeks [3] (conflict, see misc info)
Adverse effects:
1) weakness
2) headache
3) somnolence
4) nausea/vomiting
5) dry mouth
6) constipation
7) late adverse effects
a) polyuria
b) polydipsia
c) irritability
d) weight loss
Drug interactions:
1) antacids: hypermagnesemia may result in patients with renal failure
2) cholestyramine & colestipol may decrease effect of calcifediol
Mechanism of action:
1) vitamin D3 is hydroxylated in the liver to form 25-OH vit D3
2) 25-OH vitamin D3 is hydroxylated in the kidney to form 1,25- dihydroxy vitamin D3 (calcitriol), the active metabolite of vitamin D3
3) calcitriol stimulates intestinal Ca+2 & phosphate transport
4) 25-OH vitamin D is the major circulating form of vitamin D; it has only mild biologic activity.
Interactions
drug interactions
Related
25-hydroxyvitamin D3 (calcifediol) in serum
vitamin D binding protein, Gc globulin; group-specific component
General
cholecalciferol; vitamin D3
Properties
MISC-INFO: elimination route LIVER
1/2life 3-6 HOURS
Database Correlations
PUBCHEM correlations
References
- Drug Information & Medication Formulary, Veterans Affairs,
Central California Health Care System, 1st ed., Ravnan et al
eds, 1998 - not on National VA formulary
- Deprecated Reference
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015